Amlitelimab
As of the edition of 20 October 2026, Amlitelimab is an antibody: in active development; acts on TNFSF4.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2031
- Kind
- Antibody
- Registered trials
- 20, 2 stopped early
- Disease areas
- Immune system; Skin and connective tissue; Inherited and neonatal; Lungs and airways; Digestive system; Nutrition and metabolism
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TNFSF4 | Tumor necrosis factor ligand superfamily member 4 | P23510 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 4 | 4 | 0 | 0 |
| Phase 2 | 10 | 4 | 4 | 2 |
| Phase 3 | 6 | 3 | 3 | 0 |
| All trials | 20 |